ReviewNanomaterials (Basel, Switzerland)2026
From Nature to Medicine: Overcoming the Limitations of Herbal Therapeutics for Pancreatic Cancer Treatment Based on Nanotechnology.
Review in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide due to late-stage diagnosis, aggressive progression, and limited therapeutic responsiveness. Although herbal-derived bioactive compounds have demonstrated promising anticancer potential, their clinical application is often restricted by poor aqueous solubility, low bioavailability, rapid metabolic degradation, and insufficient tumor targeting. Nanomedicine has emerged as a promising platform to overcome these limitations through enhanced drug delivery, improved pharmacokinetics, and controlled release capabilities. In recent years, the integration of green nanotechnology with herbal therapeutics has gained increasing attention as a sustainable and biocompatible strategy for PDAC management. Green synthesis approaches utilizing plant extracts, microbial systems, and biopolymers provide environmentally friendly alternatives to conventional physicochemical nanoparticle (NP) fabrication methods while simultaneously enhancing biological functionality. This review aims to explore green nanotechnology-based strategies for improving the therapeutic potential of herbal-derived bioactive compounds in PDAC, with particular emphasis on nanoformulation approaches that enhance solubility, bioavailability, tumor targeting, and anticancer efficacy. In addition, the review discusses the advantages of green synthesis approaches, NP characterization strategies, translational barriers, biosafety considerations, and current clinical challenges. Overall, this review highlights the growing potential of green nanomedicine to improve herbal-based therapeutic strategies against PDAC while emphasizing the key obstacles that must be addressed to facilitate successful clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.